Information  X 
Enter a valid email address

Amryt Pharma PLC (AMYT)

  Print      Mail a friend

Friday 30 August, 2019

Amryt Pharma PLC

Director/PDMR Shareholding

RNS Number : 6214K
Amryt Pharma PLC
30 August 2019
 

 

30 August 2019

Amryt Pharma plc

("Amryt" or the "Company")

Director and PDMR share purchases

 

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that, following the announcement on 27 August 2019 with respect to, inter alia, an Interim Placing to raise $8.0 million, the 4,580,288 Initial Interim Placing Shares have been admitted to trading on AIM today.   Ray Stafford, a Non-Executive Director of the Company, subscribed for 918,273 Initial Interim Placing Shares pursuant to the Interim Placing. Following this subscription, Ray Stafford has an interest in 1,301,001 ordinary shares representing approximately 2.6 per cent. of the enlarged issued share capital of the Company.

The total issued ordinary share capital of the Company following admission of the Initial Interim Placing Shares is 50,383,169 ordinary shares. 

 

1.           

Details

of the person discharging managerial responsibilities / person closely associated

a)

Name

Ray Stafford

2.           

Reason for the notification

a)

Position / status

Non-Executive Director

b)

Initial notification / amendment

Initial notification

3.           

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

b)

Legal entity identifier

213800BOS8WAJO2BEQ38

4.           

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument,  type of instrument

Ordinary shares of £0.06 each


Identification code

GB00BDD1LS57

b)

Nature of the transaction

Purchase of ordinary shares as part of placing announced on 27 August 2019

c)

Currency

British Pounds

d)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.90

918,273


e)

Aggregated information

·      Aggregated volume

·      Aggregated price

 

918,273

£826,445.70

f)

Date of the transaction

30 August 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Dr. Joe Wiley, CEO

Rory Nealon, CFO/COO


 

Shore Capital

+44 (0) 20 7408 4090

Financial Adviser, Nominated Adviser and Joint Broker


Edward Mansfield, Mark Percy, Daniel Bush, John More

 


Stifel

+44 (0) 20 7710 7600

Joint Broker


Jonathan Senior, Ben Maddison




Davy

+353 (1) 679 6363

Euronext Growth Advisor and Joint Broker


John Frain, Daragh O'Reilly




Consilium Strategic Communications

+44 (0) 20 3709 5700

Amber Fennell, Matthew Neal, David Daley


 

All defined terms used in this announcement not otherwise defined have the meanings set out in the Admission Document dated 27 August 2019.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHCKCDKABKDDFB

a d v e r t i s e m e n t